News | RSNA | July 14, 2021

RSNA Co-sponsors Brain Tumor AI Challenge

The Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society have announced the launch of the 10th annual Brain Tumor Segmentation (BraTS) challenge

Getty Images

July 14, 2021 — The Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society have announced the launch of the 10th annual Brain Tumor Segmentation (BraTS) challenge.

The RSNA/ASNR/MICCAI BraTS 2021 challenge focuses on brain tumor detection and classification, utilizing multi-parametric magnetic resonance imaging (mpMRI) scans. It represents the culmination of a decade of BraTS challenges, offering a large and diverse dataset with detailed annotations and an important associated biomarker.

“RSNA has significantly ‘upped their game’ with this year’s Brain Tumor Classification Challenge,” said Adam E. Flanders, M.D., who serves on the RSNA Machine Learning Subcommittee. “It is our first AI Challenge to use MRI, and it is also our first to address an oncology problem — brain cancer.”

Another novel aspect of the challenge is that it addresses two very clinically relevant tasks: (1) to develop the most accurate automated method to measure the size of the visual components of a cancer—this has implications in being able to precisely track growth or response of the cancer to treatment—and (2) to develop a reliable non-invasive method to predict the presence of specific genetic features in the tumor from the MR images alone.

“These genetic markers are indicators of treatment response and survival,” Flanders said. “This has potential use in planning for customized therapies even before surgery is performed.”

Participants may choose to compete in one or both of the challenge tasks.

In the first task, Brain Tumor Segmentation, participants build models that produce detailed segmentations of brain tumor sub-regions that correspond to those created by neuroradiologists. Such segmentations could enable improvements in computer-assisted surgery, radiotherapy guidance and disease progression monitoring.

For second task, Brain Tumor Radiogenomic Classification, participants build models that use mpMRI imaging to predict MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status. Such radiogenomic models could improve the efficiency and accuracy of diagnosis, prognosis and treatment planning for patients with glioblastoma.

Glioblastoma and diffuse astrocytic glioma with molecular features of glioblastoma are the most common and aggressive malignant primary tumors of the central nervous system in adults. Glioblastoma patients have very poor prognosis, and the current standard of care comprises surgical resection followed by radiotherapy and chemotherapy. The methylation of DNA repair enzyme MGMT’s promoter in newly diagnosed glioblastoma has been identified as a favorable prognostic factor and a predictor of chemotherapy response. Determination of MGMT promoter methylation status in newly diagnosed glioblastoma can influence treatment decision making.

Final model submission is due October 12. Winners will be announced on November 23 and recognized recognized in an event in the AI Showcase Theater at RSNA 2021 on Monday, November 29. Prize money for the top entries in each task is provided by Intel, NeoSoma and RSNA.

For more information: RSNA.org/AI-image-challenge

You can find more RSNA news and content here.

Related Content

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

News | Breast Imaging | July 30, 2021
July 30, 2021 — Volpara Health, a global health technology software leader providing an integrated breast care platfo
According to ARRS’ American Journal of Roentgenology (AJR), the resources required to warm iohexol 350 to body temperature before injection for computed tomography (CT) may not be warranted, given the lack of observed practical benefit.

Values represent number of patients, with percentage in parentheses and 95% CI in brackets (not reported for levels of severity of allergic/allergic-like reactions). 95% CIs were calculated using the Clopper-Pearson exact formula. For events with zero frequency, one-sided 97.5% CIs are provided.

News | Contrast Media | July 30, 2021
If you plan to attend HIMSS21 Aug. 9-13 in Las Vegas, be sure to note that due to health and safety updates, masks will now be required for attendees and exhibitors.

Getty Images

News | HIMSS | July 28, 2021
July 28, 2021 —If you plan to attend HIMSS21 Aug.
Researchers from the School of Biomedical Engineering & Imaging Sciences at King's College London have automated brain MRI image labeling, needed to teach machine learning image recognition models, by deriving important labels from radiology reports and accurately assigning them to the corresponding MRI examinations

Getty Images

News | Magnetic Resonance Imaging (MRI) | July 28, 2021
July 28, 2021 — Researchers from the School of Biomedical Engineering & Imaging Sciences at...
A new Harvey L. Neiman Health Policy Institute study found that patients paid 12% of the costs of secondary imaging interpretation out-of-pocket. Such secondary interpretations are increasingly performed for complex patients, but patients’ liabilities and paid out-of-pocket costs were not previously known.

Getty Images

News | Radiology Imaging | July 28, 2021
July 28, 2021 — A new Harvey L.